Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma

Citation
M. Magagnoli et al., Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma, BONE MAR TR, 28(10), 2001, pp. 923-927
Citations number
30
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
0268-3369 → ACNP
Volume
28
Issue
10
Year of publication
2001
Pages
923 - 927
Database
ISI
SICI code
0268-3369(200111)28:10<923:MPOICI>2.0.ZU;2-Q
Abstract
The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine -containing regimens with G-CSF support were explored in patients with pret reated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) rec eived ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens radiotherapy. The target yield was greater t han or equal to3 x 10(6) CD34(+) cells/kg of body weight in order to suppor t the subsequent myeloablative chemotherapy. The optimal PBSC harvest occur red on days 11 and 12, with no difference in CD34+ cell mobilization kineti cs between the ifosfamide/vinorelbine and IGEV regimens. The median number of CD34(+) cells/kg body weight collected was 10.9 x 10(6) (range 1.76-61.1 x 10(6)). The median total CD34(+) cell/mul, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/mul, 10 x 10(4)/kg, and 17 90 0/mul, respectively. The target yield of CD34(+) cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-r elated hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy re gimen with G-CSF support can be successfully and safely used to mobilize PB SCs.